Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase

Drug Metabolism and Disposition

Volumn 41, Issue 1, 2013, Pages 24-29

  Barr, John T ^a   Jones, Jeffrey P ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE OXIDASE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; PHTHALAZINE DERIVATIVE; RALOXIFENE;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; FEMALE; HUMAN; IN VITRO STUDY; INHIBITION KINETICS; LIVER CYTOSOL; MALE; MOLECULAR PROBE; OXIDATION KINETICS; PRIORITY JOURNAL;

ALDEHYDE OXIDASE; AMINOACRIDINES; CHROMATOGRAPHY, LIQUID; ENZYME INHIBITORS; HUMANS; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; OXIDATION-REDUCTION;

EID: 84871575600     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048546     Document Type: Article

References (18)

1. Atwell GJ, Rewcastle GW, Baguley BC, and Denny WA (1987) Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem 30:664-669. (Pubitemid 17065201)
2. Barr JT and Jones JP (2011) Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions. Drug Metab Dispos 39:2381-2386.
3. Cook PB and Cleland WW (2007) Enzyme Kinetics and Mechanism, Garland Science, New York.
4. Foti RS, Rock DA, Wienkers LC, and Wahlstrom JL (2010) Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos 38:981-987.
5. Foti RS and Wahlstrom JL (2008) CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos 36:523-528. (Pubitemid 351397977)
6. Garattini E and Terao M (2012) The role of aldehyde oxidase in drug metabolism. Expert Opin Drug Metab Toxicol 8:487-503.
7. Hochner-Celnikier D (1999) Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol 85:23-29.
8. Hutzler JM, Yang YS, Albaugh D, Fullenwider CL, Schmenk J, and Fisher MB (2012) Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab Dispos 40:267-275.
9. Kitamura S, Sugihara K, and Ohta S (2006) Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83-98.
10. Obach RS (2004) Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32:89-97.
11. Obach RS, Huynh P, Allen MC, and Beedham C (2004) Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 44:7-19. (Pubitemid 38005089)
12. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348. (Pubitemid 41832613)
13. Panoutsopoulos GI, Kouretas D, and Beedham C (2004) Contribution of aldehyde oxidase, xanthine oxidase, and aldehyde dehydrogenase on the oxidation of aromatic aldehydes. Chem Res Toxicol 17:1368-1376. (Pubitemid 39403051)
14. Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, and Tran T-D (2010) Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53:8441-8460.
15. Schofield PC, Robertson IG, Paxton JW, McCrystal MR, Evans BD, Kestell P, and Baguley BC (1999) Metabolism of N-[2-(dimethylamino)ethyl]acridine-4- carboxamide in cancer patients undergoing a phase I clinical trial. Cancer Chemother Pharmacol 44:51-58. (Pubitemid 29246325)
16. Strelevitz TJ, Orozco CC, and Obach RS (2012) Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance. Drug Metab Dispos 40:1441-1448.
17. Torres RA, Korzekwa KR, McMasters DR, Fandozzi CM, and Jones JP (2007) Use of density functional calculations to predict the regioselectivity of drugs and molecules metabolized by aldehyde oxidase. J Med Chem 50:4642-4647. (Pubitemid 47463238)
18. Tucker GT, Houston JB, and Huang S-M (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Pharm Res 18:1071-1080. (Pubitemid 32900389)